Brain, Obesity, Dopamine and You Study (BODY)
Primary Purpose
Obesity
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
meal replacements, psychotherapy, dietary education
Sponsored by

About this trial
This is an interventional treatment trial for Obesity focused on measuring Obesity
Eligibility Criteria
Inclusion Criteria:
- 41 obese adults (BMI 33 kg - 45 kg.)
- 24 lean adults (BMI 18.5 kg - 24.9 kg.)
Exclusion Criteria:
Subjects who are:
- smokers,
- pregnant or lactating, postmenopausal,
- have diabetes or impaired oral glucose tolerance (fasting blood glucose level of < 100 mg/dl and a 2 hour post-glucose challenge plasma glucose level of < 140mg/dl, per ADA criteria; ADA 2004),
- significant organ system dysfunction, anemia (Hb <10 g/dl),
- take medications that could influence the study results, any history of dopamine agonist or antagonist treatment (e.g. neuroleptics or metoclopramide),
- parkinsonism on exam,
- borderline or lower IQ (<80 full scaled score), or
- any psychiatric or neurologic illness (e.g. drug abuse, Parkinson disease, Tourette syndrome, stroke) that could affect the interpretation of the data, compliance or completion of the study will be excluded. Specific psychiatric exclusions are lifetime psychosis, current mania, substance dependence, major depression, social phobia, tic disorders, eating disorders and panic disorder. Dysthymia will not be excluded, but levels of depression will be measured with the BDI for future exploratory analysis.
- Lean subjects will be excluded for being obese in the past (based on maximum BMI not related to pregnancy).
Sites / Locations
- Washington University Medical School
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
Obese group - Group 1
Lean group - Group 2
Arm Description
If you have a BMI between 33kg - 45kg and weight under 350 lbs you could be in group 1.
If you have a BMI between 18.5 kg - 24.9 kg you could be in group 2.
Outcomes
Primary Outcome Measures
To determine the status of postsynaptic D2-like receptor binding in humans with obesity.
To test this hypothesis, we will measure D2-like receptor binding with PET and a specific, non-competitive D2-like receptor ligand NMB in obese and lean individuals.
Secondary Outcome Measures
To determine the relationship between D2-like receptor binding, reward sensitivity and hedonic response to sweet tastes.
To test this hypothesis we will correlate D2-like receptor binding levels in the striatum with reward questionnaires and standardized assessments of sweet taste responses within each group.
Full Information
NCT ID
NCT01094756
First Posted
March 17, 2010
Last Updated
October 31, 2016
Sponsor
Washington University School of Medicine
Collaborators
National Institutes of Health (NIH)
1. Study Identification
Unique Protocol Identification Number
NCT01094756
Brief Title
Brain, Obesity, Dopamine and You Study
Acronym
BODY
Official Title
Central Dopamine Receptors In Obesity
Study Type
Interventional
2. Study Status
Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
July 2010 (undefined)
Primary Completion Date
June 2015 (Actual)
Study Completion Date
October 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine
Collaborators
National Institutes of Health (NIH)
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Central dopamine is thought to play a significant role in obesity. In support of this idea, animal studies and one human positron emission tomography (PET) study have found reduced postsynaptic D2-like receptor availability in the striatum in obesity, with lower D2 receptor availability associated with higher weight. In addition, reward sensitivity and hedonic responses, known to be related to dopamine function, have also been implicated in obesity and obesity-related eating behavior. These reports have led to the concept that dopaminergic abnormalities (e.g. reduced D2-like receptors) influence reward sensitivity, leading to altered eating behaviors and eventually obesity. However, there are several critical limitations of the human D2 receptor studies that limit the strength of their conclusions and thus the interpretations and speculations embedded in literature that relies on this work. First, estimates of D2-like receptors in humans have been confounded by potential differences in endogenous dopamine release since the PET ligand (raclopride) used is known to be displaceable from receptors by endogenous dopamine. Second, failure to rigorously screen obese individuals for diabetes confounds conclusions, since diabetes has been independently associated with dopaminergic abnormalities such as reduced D2-like receptors and muted dopamine release in diabetic rats. Finally, no human studies have addressed whether reduced D2-like receptor levels are a risk factor for obesity, a consequence of engaging in obesity-related behaviors or being obese or all of the above.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
82 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Obese group - Group 1
Arm Type
Active Comparator
Arm Description
If you have a BMI between 33kg - 45kg and weight under 350 lbs you could be in group 1.
Arm Title
Lean group - Group 2
Arm Type
No Intervention
Arm Description
If you have a BMI between 18.5 kg - 24.9 kg you could be in group 2.
Intervention Type
Dietary Supplement
Intervention Name(s)
meal replacements, psychotherapy, dietary education
Intervention Description
After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
Primary Outcome Measure Information:
Title
To determine the status of postsynaptic D2-like receptor binding in humans with obesity.
Description
To test this hypothesis, we will measure D2-like receptor binding with PET and a specific, non-competitive D2-like receptor ligand NMB in obese and lean individuals.
Time Frame
1 year for each participant
Secondary Outcome Measure Information:
Title
To determine the relationship between D2-like receptor binding, reward sensitivity and hedonic response to sweet tastes.
Description
To test this hypothesis we will correlate D2-like receptor binding levels in the striatum with reward questionnaires and standardized assessments of sweet taste responses within each group.
Time Frame
1 year per participant
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
41 obese adults (BMI 33 kg - 45 kg.)
24 lean adults (BMI 18.5 kg - 24.9 kg.)
Exclusion Criteria:
Subjects who are:
smokers,
pregnant or lactating, postmenopausal,
have diabetes or impaired oral glucose tolerance (fasting blood glucose level of < 100 mg/dl and a 2 hour post-glucose challenge plasma glucose level of < 140mg/dl, per ADA criteria; ADA 2004),
significant organ system dysfunction, anemia (Hb <10 g/dl),
take medications that could influence the study results, any history of dopamine agonist or antagonist treatment (e.g. neuroleptics or metoclopramide),
parkinsonism on exam,
borderline or lower IQ (<80 full scaled score), or
any psychiatric or neurologic illness (e.g. drug abuse, Parkinson disease, Tourette syndrome, stroke) that could affect the interpretation of the data, compliance or completion of the study will be excluded. Specific psychiatric exclusions are lifetime psychosis, current mania, substance dependence, major depression, social phobia, tic disorders, eating disorders and panic disorder. Dysthymia will not be excluded, but levels of depression will be measured with the BDI for future exploratory analysis.
Lean subjects will be excluded for being obese in the past (based on maximum BMI not related to pregnancy).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tamara Hershey, Ph.D.
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington University Medical School
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Brain, Obesity, Dopamine and You Study
We'll reach out to this number within 24 hrs